H.C. Wainwright lowered the firm’s price target on Nuvation Bio (NUVB) to $17 from $18 and keeps a Buy rating on the shares. The firm says the company’s Q4 Ibtrozi sales were inline with estimates.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NUVB:
- Nuvation Bio Expands Global Reach with Eisai Partnership
- Nuvation Bio, Eisai enter exclusive taletrectinib license agreement
- Nuvation Bio initiated with a Neutral at UBS
- Nuvation Bio price target raised to $18 from $10 at H.C. Wainwright
- Nuvation Bio’s IBTROZI Gains Buy Rating Amid Increased Market Penetration and Extended Therapy Duration